TR2022015809A2 - A HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES, A METHOD FOR PRODUCTION OF HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE - Google Patents

A HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES, A METHOD FOR PRODUCTION OF HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE

Info

Publication number
TR2022015809A2
TR2022015809A2 TR2022/015809A TR2022015809A TR2022015809A2 TR 2022015809 A2 TR2022015809 A2 TR 2022015809A2 TR 2022/015809 A TR2022/015809 A TR 2022/015809A TR 2022015809 A TR2022015809 A TR 2022015809A TR 2022015809 A2 TR2022015809 A2 TR 2022015809A2
Authority
TR
Turkey
Prior art keywords
humanin
nanoparticle
treatment
lipide
loaded solid
Prior art date
Application number
TR2022/015809A
Other languages
Turkish (tr)
Inventor
Rüya Topal Gi̇zem
Bozkir Asuman
Küçüktürkmen Berri̇n
Can Öz Umut
Güneş Özhan Hati̇ce
Kaan Poyraz Yusuf
Original Assignee
Izmir Biyotip Ve Genom Merkezi
İzmi̇r Bi̇yotip Ve Genom Merkezi̇
Saglik Bilimleri Ueniversitesi
Sağlik Bi̇li̇mleri̇ Üni̇versi̇tesi̇
T C Ankara Ueniversitesi Rektoerluegue
Tcankara Üni̇versi̇tesi̇ Rektörlüğü
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Izmir Biyotip Ve Genom Merkezi, İzmi̇r Bi̇yotip Ve Genom Merkezi̇, Saglik Bilimleri Ueniversitesi, Sağlik Bi̇li̇mleri̇ Üni̇versi̇tesi̇, T C Ankara Ueniversitesi Rektoerluegue, Tcankara Üni̇versi̇tesi̇ Rektörlüğü filed Critical Izmir Biyotip Ve Genom Merkezi
Priority to TR2022/015809A priority Critical patent/TR2022015809A2/en
Publication of TR2022015809A2 publication Critical patent/TR2022015809A2/en
Priority to PCT/TR2023/051123 priority patent/WO2024085841A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Buluş, moleküler nörofarmakoloji teknik alanlarına ait olup; nöroloji hastalıklarından müzdarip hasta kişilerin tedavinin sağlanabilmesi için etken maddenin kan beyin engelinin geçilmesine olanak sağlayan, hastalık bölgesine daha fazla etken madde geçişi sağlayarak tedavinin etkinliğinin arttırıldığı, biyouyumlu bir Humanin yüklü katı lipit nanopartikül ve bunun üretimi ve bunun nöroloji hastalıklarının tedavisinde veya bu hastalıklardan kaynaklanan semptomlarında kullanılması ile ilgilidir.The invention belongs to the technical fields of molecular neuropharmacology; Production of a biocompatible Humanin-loaded solid lipid nanoparticle and its use in the treatment of neurology diseases or the symptoms caused by these diseases, which allows the active substance to pass through the blood-brain barrier in order to provide treatment for patients suffering from neurology diseases, to increase the effectiveness of the treatment by providing more active substance passage to the disease area, and to increase the effectiveness of the treatment. It is related to.

TR2022/015809A 2022-10-18 2022-10-18 A HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES, A METHOD FOR PRODUCTION OF HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE TR2022015809A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2022/015809A TR2022015809A2 (en) 2022-10-18 2022-10-18 A HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES, A METHOD FOR PRODUCTION OF HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE
PCT/TR2023/051123 WO2024085841A1 (en) 2022-10-18 2023-10-16 A humanin-loaded solid lipid nanoparticle for use in the treatment of neurological diseases and a method for producing the humanin-loaded solid lipid nanoparticle

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2022/015809A TR2022015809A2 (en) 2022-10-18 2022-10-18 A HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES, A METHOD FOR PRODUCTION OF HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE

Publications (1)

Publication Number Publication Date
TR2022015809A2 true TR2022015809A2 (en) 2022-10-21

Family

ID=85162471

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2022/015809A TR2022015809A2 (en) 2022-10-18 2022-10-18 A HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES, A METHOD FOR PRODUCTION OF HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE

Country Status (2)

Country Link
TR (1) TR2022015809A2 (en)
WO (1) WO2024085841A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054544A2 (en) * 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
EP2706989A1 (en) * 2011-05-09 2014-03-19 Instituto Químico De Sarrià Polymeric nanoparticles for drug delivery

Also Published As

Publication number Publication date
WO2024085841A1 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
Hu et al. Pyroptosis, and its role in central nervous system disease
Ni et al. IL-17A contributes to perioperative neurocognitive disorders through blood-brain barrier disruption in aged mice
Zhao et al. Therapeutic potential of an anti-high mobility group box-1 monoclonal antibody in epilepsy
Cui et al. Enhancement of radiotherapy efficacy by docetaxel-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer
Pfab et al. Repurposing of antimicrobial agents for cancer therapy: what do we know?
Nguyen et al. Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury
Xu et al. Modulation of LPA1 receptor-mediated neuronal apoptosis by Saikosaponin-d: A target involved in depression
DE602006014691D1 (en) DIAGNOSIS, TREATMENT AND PREVENTION OF VASCULAR DISEASES USING IL-1alpha AUTOANTIC BODIES
Kuang et al. Treatment of early brain injury after subarachnoid hemorrhage in the rat model by inhibiting p53-induced ferroptosis
EA201190043A1 (en) IMIDAZOPIRASINE INHIBITORS SYK
AU2008292407B2 (en) Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
Bao et al. Lentinan produces a robust antidepressant-like effect via enhancing the prefrontal Dectin-1/AMPA receptor signaling pathway
Das et al. Promise of the NLRP3 inflammasome inhibitors in in vivo disease models
Wei et al. Dihydromyricetin improves LPS-induced sickness and depressive-like behaviors in mice by inhibiting the TLR4/Akt/HIF1a/NLRP3 pathway
Zhang et al. Lemon-derived extracellular vesicle-like nanoparticles block the progression of kidney stones by antagonizing endoplasmic reticulum stress in renal tubular cells
Gazerani Antipruritic effects of botulinum neurotoxins
Ding et al. Advanced oxidative protein products cause pain hypersensitivity in rats by inducing dorsal root ganglion neurons apoptosis via NADPH oxidase 4/c-Jun N-terminal kinase pathways
Wang et al. A new gentiopicroside derivative improves cognitive deficits of AD mice via activation of Wnt signaling pathway and regulation of gut microbiota homeostasis
Ji et al. Inhibition of MMP-2 and MMP-9 attenuates surgery-induced cognitive impairment in aged mice
TR2022015809A2 (en) A HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES, A METHOD FOR PRODUCTION OF HUMANIN-LOADED SOLID LIPIDE NANOPARTICLE
Navneet et al. Exploring the therapeutic potential of elastase inhibition in age-related macular degeneration in mouse and human
Fei et al. Intermittent hypoxia mimicking obstructive sleep apnea aggravates early brain injury following ICH via neuroinflammation and apoptosis
Khair et al. New insights into the mechanism of alcohol-mediated organ damage via its impact on immunity, metabolism, and repair pathways: A summary of the 2021 Alcohol and Immunology Research Interest Group (AIRIG) meeting
Chang et al. A purine antimetabolite attenuates toll-like receptor-2,-4, and subarachnoid hemorrhage-induced brain apoptosis
Ali et al. Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer’s disease